InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,949.17
(
0.00%
)
US TECH 100
20,154.40
(
-0.95%
)
Dow Jones
43,750.86
(
0.00%
)
Brent Oil
71.75
(
-0.64%
)
Bitcoin
89,509.83
(
2.47%
)
Post# of 253612
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120725
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: flatlander_60048 post# 92784

Friday, 03/19/2010 11:59:20 PM

Friday, March 19, 2010 11:59:20 PM

Post# of 253612

Teva indicates it is more concerned about new oral treatments entering the MS market [than it is about generic Copaxone].

This is pure spin, IMO; behind closed doors, I think Teva is more much concerned about generic Copaxone.

Either way I think NVS is positioned to challenge Copaxone. How do you handicap the odds that FTY720 gets approved in 2010.

For the US, about 40%; for the EU (where the review time is longer), about 25%. JMHO, FWIW


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up